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approach of Otsuko, the company 
that produces delamanid, a drug for 
the treatment of MDR tuberculosis, 
has been even worse. Approved by 
the European and Japanese regulatory 
agencies in 2014, delamanid has 
filed registration in only Europe, 
Japan, and South Korea. The drug is 
marketed in the UK and Germany only, 
at a price of $28 000 for a 6-month 
course of treatment in the UK. More 
importantly, patients in low-income 
and middle-income countries have no 
access to this drug. 
Fortunately there is a charted path 
in another direction. The UNITAID 
Medicines Patent Pool (MPP) has 
been a model for best practice in the 
area of sharing intellectual property 
to improve drug access. Since July, 
2010, UNITAID has sought voluntary 
licences for technologies related to 
HIV, and as of December, 2015, 12 
antiretrovirals have been placed in 
the patent pool for licensing. More 
than 50 sublicensing agreements 
have been completed to allow rapid 
production of generic drug and 
lower prices.7 The model delinks the 
price of drug development from 
the eventual price a patient pays by 
allowing generic drug companies to 
compete. In November, 2015, the 
MPP expanded its mandate to include 
voluntary licensing for hepatitis C 
and tuberculosis medicines. This non-
exclusive licensing model can be easily 
borrowed and applied by academic 
institutions like Johns Hopkins 
University. 
Johns Hopkins School of Public 
Health turns 100 years old in 2016. 
I am proud of the institution and its 
legacy over the past century. But a 
centennial celebration must be as 
much about the promise of the future 
as it is about the achievements of 
the past. Insisting on non-exclusive 
licensing would be an unforgettable 
toast.
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To be or not 
to be exclusive: 
the sutezolid story
I arrived at the Johns Hopkins 
University campus with a sense of 
déjà vu; it was my first visit to my 
alma mater in years. I had travelled 
to Baltimore for a meeting about 
the licensing of sutezolid, a much-
awaited drug candidate for treatment 
of Mycobacterium tuberculosis. The 
research faculty, technology transfer 
officers, university administration, 
and advocates at the meeting felt the 
weight of the responsibility. We knew 
that licensing a tuberculosis drug 
candidate could be a historic event.
Frustratingly, in the past 40 years the 
world has added only two new drugs 
to the arsenal against tuberculosis, the 
second most deadly infectious disease 
on the planet.1 The statistics are 
infuriating: more than 9 million people 
developed tuberculosis in 2013, and an 
estimated 44% of those in countries 
such as the Philippines, Thailand, and 
South Korea have resistance to at 
least one of the second-line agents for 
tuberculosis treatment.2 Horrifically, 
only one of two people treated for 
multidrug resistant (MDR) tuberculosis 
are cured,1 and the toxic 2-year 
treatment regimen involves thousands 
of pills and hundreds of injections. For 
extensively drug resistant tuberculosis 
(XDR-TB) the cure rate drops to 20%.
With new agents like sutezolid being 
used in combination with other drugs, 
we might be on the brink of being able 
to save more lives with less toxicity. 
Sutezolid, originally U-100480, began 
development alongside linezolid in 
1996. Even then it showed favourable 
pharmacokinetic properties, efficacy 
against drug-resistant strains of 
tuberculosis, and low toxicity in rat 
models. 3 
After lying undeveloped for several 
years in the hands of Pfizer and 
others, there is a new window of 
opportunity for the drug. Sequella, a 
pharmaceutical corporation, acquired 
the licence for the development and 
commercialisation of sutezolid from 
Pﬁ zer in 2011. However, Johns Hopkins 
University still owns some key pieces 
of the intellectual property. 
Despite more than 2 years of 
discussions with public health 
advocates and civil society, it seems 
that Johns Hopkins plans to licence 
exclusively its intellectual property 
around sutezolid to bring this 
compound to market. Unfortunately, 
an exclusive licensing plan would 
not only inhibit development of a 
MDR tuberculosis regimen but could 
also result in a highly priced and 
inaccessible product. Two recent drugs 
provide prescient examples of the 
need for non-exclusive licensing. 
Bedaquiline, approved by the US 
Food and Drug Administration (FDA) 
in 2012, was recently added to a 
Médecins Sans Frontières treatment 
regimen in Armenia. Here, the 
sputum clearance rate at 6 months’ 
follow-up4 was 84% in patients with 
drug resistance,4 which compares 
favourably with the usual 50% average 
successful treatment rate for MDR 
tuberculosis.1 
Unfortunately, in March, 2015, it 
was estimated that only 1000 patients 
had received bedaquiline.5 Janssen, the 
company that makes the drug, charges 
US$900 and $3000 for a course of 
this drug in low-income and middle-
income countries, respectively, and 
$30 000 in the USA. These prices have 
left poorly funded health departments 
desperate, unable to scale-up treatment 
programmes. Furthermore in March, 
2015, Janssen had registered the drug 
in only 21 countries. The high prices for 
bedaquiline are especially infuriating 
given that Janssen received a priority 
review voucher from the FDA and that 
the drug was fast-tracked through FDA 
approval.6 This price barrier has been 
temporarily removed with a donation 
plan, but programmes like this one are 
often unsustainable and countries not 
included in the plan still face high prices.
If the story of bedaquiline’s release 
to the market is worrying, then the 
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